IMUX (Immunic) Total Operating Expense: $109.64 Mil (TTM As of Mar. 2026)


IMUX Immunic Inc IMUX
32 GF Score
Price $15.15
! 3 Warning Signs
View Full Analysis

What is Immunic Total Operating Expense?

Immunic IMUX +1.53% 32 Total Operating Expense is $109.64 Mil as of Mar. 2026. GuruFocus rates IMUX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Immunic's Total Operating Expense for the three months ended in Mar. 2026 was $33.24 Mil. Immunic's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $109.64 Mil.

Immunic Total Operating Expense Related Terms

Immunic Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Immunic's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunic Total Operating Expense Chart

Immunic Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 91.67 86.52 99.22 98.05 103.23

Immunic Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.83 27.08 25.99 23.33 33.24
IMUX
32GF Score
Immunic Inc IMUX
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immunic Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $109.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $109.64 Mil mean?
Immunic (IMUX) has a Total Operating Expense of $109.64 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Immunic and its competitors.
Is Immunic's Total Operating Expense too high?
Immunic's current Total Operating Expense is $109.64 Mil. Overall, Immunic has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Immunic's Total Operating Expense compare to KPTI and INDP?
Immunic's Total Operating Expense of $109.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Immunic and its competitors. Immunic's current Total Operating Expense is $109.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunic stock overvalued right now?
Immunic (IMUX) has a current Total Operating Expense of $109.64 Mil. The current Total Operating Expense is $109.64 Mil. Immunic's overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Immunic (IMUX), the current Total Operating Expense is $109.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Immunic Business Description

Other Exchanges 10V:Germany
Address 1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
32GF Score

Get the complete analysis for IMUX

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.15
Price